Document:

SEC Connect

***Text Omitted and Filed Separately

with the Securities and Exchange Commission.

Confidential Treatment Requested

Under 17 C.F.R. Sections 200.80(b)(4) and Rule 24b-2 of
the

Securities Act of 1934, as amended.

 

Exhibit 10.10

FIRST
AMENDMENT TO

CHROMADEX,
INC. - DARTMOUTH EXCLUSIVE LICENSE AGREEMENT

 THIS
FIRSTAMENDMENT (“Amendment”) is effective as of
June 13, 2016, by and between the TRUSTEES OF DARTMOUTH COLLEGE, a
non-profit educational and research institution existing under the
laws of the State of New Hampshire (hereinafter
“Dartmouth”) and CHROMADEX INC. having its principal
place of business at 10005 Muirlands Blvd., Suite G, Irvine,
California 92618; hereinafter called Company. (hereinafter
“Company”).

WHEREAS, the parties previously entered
into an Exclusive License Agreement, dated May 16, 2014 (the
“Agreement”);

WHEREAS, the parties desire to amend
said Agreement as set forth herein;

NOW, THEREFORE, in consideration of the
premises and the covenants herein contained, the parties hereby
agree to amend the Agreement as follows:

1. 

Section 5.01(d)
shall be deleted in its entirety and replaced with the
following:

 

 (d) Company
shall pay the following percentages of any consideration received
from each sublicense (e.g., license issue fees, license maintenance
fees, lump sum payments in lieu of royalty payments, stocks, earned
royalty on sublicensee’s sales, etc.) received from each
sublicensee of Company for the grant of a sublicense determined by
the date of the sublicense and payable upon Company's receipt of
the consideration thereof:

 

          
i.   Sublicense agreement executed before filing an IND
except as noted in ii below     
                                            
     [...***...]*%

 

         
ii.   Sublicense agreements executed before filing an IND
in the field of Cockayne Syndrome and Muscular
myopathy [...***...]%

 

         iii.  
Following the first dosing of a patient in a Phase I Clinical Trial
and prior to the first dosing of a patient in a Phase II Clinical
Trial [...***...]%

 

   
     iv.   Following the first dosing
of a patient in a Phase II Clinical Trial and prior to the first
dosing of a patient in a Phase III Clinical Trial 
[...***...]%

 

   
     v.   Following the first dosing
of a patient in a Phase III Clinical Trial and prior to the
issuance by the FDA (or foreign equivalent) of approval for
marketing of a Licensed Product 
[...***...]%

 

   
     vi.   After the issuance by the
FDA (or foreign equivalent) of approval for marketing of a Licensed
Product  [...***...]%

 

 

 
***Confidential Treatment
Requested

 

 

 

If the
Company is required to enter into an agreement with a third party
to make, use or sell a Licensed Product, and such agreement
requires that the Company pay a share of sublicense income to such
third party, the percentages set forth in this section shall be
multiplied by the “Sublicense Share Adjustment” which
is calculated as follows: the Sublicense Share Adjustment equals
the fraction A% / (A%+B%), where “A%” equals the
unadjusted percentage of sublicense income payable to Dartmouth,
per the above schedule, and “B%” equals the unadjusted
total percentage of sublicense income payable to such third
parties. Notwithstanding the foregoing, under no circumstances
shall the sublicense share payable to Dartmouth be less than 50% of
the unadjusted share, and the Dartmouth earned royalty on the sale
of Licensed Product by a sublicensee shall not be less than
[...***...]% of the Net Sales.

 

All
other terms and conditions of the Agreement shall remain in full
force and effect.

 

 

 

 

This space left intentionally blank. Signatures follow on next
page.

 

 

 
***Confidential Treatment
Requested

 

 

 

 

IN WITNESS WHEREOF, the parties have
duly executed this Amendment in duplicate originals, by their
respective officers hereunto duly authorized, as of the date herein
written. As agreed by the undersigned, this Amendment may be
executed in any number of counterparts, each of which shall be
deemed an original as against any party whose signature appears
thereon, and all of which shall together constitute one and the
same instrument. Moreover, delivery of an executed counterpart of a
signature page to this Amendment by facsimile, scan or other means
of electronic image transmission and any printed record made
thereof shall be as effective as delivery of manually executed
counterpart of this Amendment.

 

 

	
 CHROMADEX,
INC.

	
 

	
TRUSTEES
OF DARTMOUTH COLLEGE

	
 

	
 

	
 

	
 By: /s/ Tom Varvaro

 Name:
Tom Varvaro  

 Title:
CFO

 

 Date:
6/14/16

	
 

	
By: /s/ Nila Bhakuni

Name: Nila
Bhakuni

Title:
Director, Technology Transfer

 

Date:
6/13/16ex10a.htm

Exhibit (10)(a)

Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm

We consent to the reference to our firm under the caption “Independent Registered Public Accounting Firm” in Post-Effective Amendment No. 13 to the 1933 Act Registration Statement (Form N-4 No. 333-181615) and Amendment No. 434 to the 1940 Act Registration Statement (Form N-4 No. 811-05721), and to the use therein of our reports dated (a) March 31, 2016, with respect to the consolidated financial statements of The Lincoln National Life Insurance Company and (b) April 12, 2016, with respect to the financial statements of Lincoln National Variable Annuity Account H for the interests in a separate account under individual flexible payment deferred variable annuity contracts.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

November 10, 2016EX-10.1

 Exhibit 10.1 

Effective: November 10, 2016 through 2017 Annual General Meeting 

WAVE LIFE SCIENCES LTD. 

NON-EMPLOYEE DIRECTOR COMPENSATION POLICY 
  

	A.	Introduction 

 The Board of Directors (the “Board”) of WAVE Life
Sciences Ltd. (the “Company”) has approved the following Non-Employee Director Compensation Policy (this “Policy”), which establishes compensation to be paid to non-employee directors of the Company to provide an
inducement to obtain and retain the services of qualified persons to serve as members of the Board.1 This Policy shall be effective as of November 10, 2016 (the “Effective
Time”) through the date of the Company’s 2017 annual general meeting of shareholders, at which time the shareholders of the Company will be asked to approve the key parameters of a new or extended version of this Policy. Subject to
receipt of shareholder approval, such new or extended policy shall take effect and govern the compensation of Outside Directors (as defined below) until the Company’s next annual general meeting of shareholders and that cycle will continue from
annual general meeting to annual general meeting. 
  

	B.	Applicable Persons 

 This Policy shall apply to each director of the Company who
is not an employee of the Company or any Affiliate (each, an “Outside Director”). “Affiliate” shall mean a corporation which is a direct or indirect parent or subsidiary of the Company, as determined pursuant to
Section 424 of the Internal Revenue Code of 1986, as amended. 
  

	C.	Equity Compensation - Share Option Grants  

 All share amounts set forth herein
shall be subject to automatic adjustment in the event of any share split or other recapitalization affecting the Company’s ordinary shares (the “Ordinary Shares”) following the Effective Time. 

 

	(1)	Initial Share Option Grants for Newly Appointed or Elected Directors 

 Each new Outside
Director appointed or elected on or after the Effective Time shall be granted a non-qualified share option to purchase 18,000 Ordinary Shares under the Company’s 2014 Equity Incentive Plan (the “2014 Plan”) on the date of his
or her initial appointment or election to the Board (an “Initial Share Option Grant”). Initial Share Option Grants shall (i) vest as to 25% on the first anniversary of the grant date and vest as to the remaining 75% on a
monthly basis thereafter for the next three years, subject to the Outside Director’s continued service on the Board; provided that such options shall become exercisable in full immediately prior to and contingent upon the closing of a
Change of Control of the Company (as defined in the option agreement); (ii) have an exercise price equal to the fair market value of the Ordinary Shares on the grant date; (iii) expire and no longer be exercisable after the five-year
anniversary of the grant date; and (iv) contain such other terms and conditions as the Board or the Compensation Committee shall determine. 

 

	1 	This Policy was formulated and approved by the Board within the limits approved by the Company’s shareholders at the 2016 annual general meeting held on August 18, 2016. 

	(2)	Annual Share Option Grants 

 On the Effective Date, each Outside Director (other than a
new Outside Director who receives an Initial Share Option Grant) shall be granted a non-qualified share option to purchase 9,000 Ordinary Shares under the 2014 Plan (an “Annual Share Option Grant”). In addition, subject to receiving
shareholders’ approval at the 2017 annual general meeting, each eligible Outside Director shall be granted an Annual Share Option Grant on the date of the 2017 annual general meeting. Annual Share Option Grants shall (i) vest as to 100% on
the first anniversary of the grant date, subject to the Outside Director’s continued service on the Board; provided that such options shall become exercisable in full immediately prior to and contingent upon the closing of a Change of
Control of the Company (as defined in the option agreement); (ii) have an exercise price equal to the fair market value of the Ordinary Shares on the grant date; (iii) expire and no longer be exercisable after the five-year anniversary of
the grant date; and (iv) contain such other terms and conditions as the Board or the Compensation Committee shall determine. 
  

	D.	Cash Compensation  

  

	(1)	Annual Cash Fees 

 The following annual cash fees shall be paid to the Outside Directors
serving on the Board and the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, as applicable provided that each non-employee director who receives cash fees as a committee member is an independent director
pursuant to the definition promulgated by the NASDAQ Stock Market. 
  

									
	 Board or Committee of Board
	  	Annual Amount for Chair	 	  	Annual Amount for Member	 
	 Board
	  	$	60,000	  	  	$	35,000	  
	 Audit Committee
	  	$	15,000	  	  	$	7,500	  
	 Compensation Committee
	  	$	10,000	  	  	$	5,000	  
	 Nominating and Corporate Governance Committee
	  	$	8,000	  	  	$	4,000	  

  

	(2)	Payment Terms for All Cash Fees 

 Cash fees payable to Outside Directors shall be paid
quarterly in arrears as of the last day of each fiscal quarter commencing on the later of the Effective Time or an Outside Director’s first election or appointment to the Board, prorated from the Effective Time or such Outside Director’s
election or appointment date, as applicable. If an Outside Director dies, resigns or is removed during any quarter, he or she shall be entitled to a cash fee on a prorated basis through his or her last day of service. 

 

	E.	Expenses 

 Upon presentation of documented expenses, reasonably satisfactory to
the Company, each Outside Director shall be reimbursed for his or her reasonable, documented out-of-pocket business expenses incurred in connection with attending meetings of the Board and Committees thereof, or general meetings of shareholders, or
in connection with other business related to the Board. 
  

	F.	Amendments 

 The Compensation Committee or the Board shall review this Policy from
time to time to assess whether any changes in the type or amount of compensation provided herein should be adjusted in order to fulfill the objectives of this Policy, provided, however, that changes to this Policy which require
shareholder approval under applicable law shall require such shareholder approval to be obtained before taking effect.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00264-of-00352.parquet"}]]